Immune Response of Asymptomatic EHPAD Employees Infected With COVID-19 (SERASYMPTO)
Kinetic of Humoral Immune Response of Asymptomatic Nursing Homes (EHPAD) Employees Infected With Severe Acute Respiratory Syndrome Coronavirus : a Case Control Study
The investigators performed in April 2020, a screening campaign of asymptomatic staff working in elderly nursing homes in Paris France (EHPAD), where the virus had been circulating actively in March and April 2020. Among 241 employees tested in four nursing homes, 32 (13.2%) were asymptomatic carriers of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2).
Few data are available concerning the humoral immune response of asymptomatic carriers, the elicitation and duration of neutralizing antibodies and the duration of protection.
The purpose of the study is to determine whether these asymptomatic persons develop a humoral immune response, whether this immune response is durable and whether it is protective against the risk of reinfection
調査の概要
詳細な説明
The investigators performed in April 2020, a screening campaign of asymptomatic staff working in elderly nursing homes in Paris, France, where the virus had been circulating actively in March and April 2020. Among 241 employees tested in four nursing homes, 32 (13.2%) were asymptomatic carriers of SARS-Cov-2.
Few data are available concerning the humoral immune response of asymptomatic carriers, the elicitation and duration of neutralizing antibodies and the duration of protection.
The main objective of this study is to describe the SARS-Cov-2 asymptomatic employees with positive immunoglobulin G (igG) serology at month 1-2 post infection.
Secondary objectives are
- To describe the proportion of asymptomatic persons with SARS-Cov-2 antibodies month 3 and 6 post infection
- To compare the proportion of persons with SARS-Cov-2 antibodies between asymptomatic and asymptomatic carriers at M1-2 post infection, M3 and M6 post infection
- To determine the factors associated with the appearance of antibodies ( viral load, age, sex, previous history, habitus..)
- To study the neutralizing capacities and immune-profiling of SARS-Cov-2 antibodies in vitro
- To evaluate the occurrence of Coronavirus Disease 2019 (COVID-19) reinfections in asymptomatic carriers during the second wave.
The design will be a case control study between
- Cases: SARS-Cov-2 asymptomatic nursing homes employees
- Controls: cohort of patients with a symptomatic COVID-19, preferably recruited in nursing homes or in case of difficulties in the virology service of COCHIN Hospital.
研究の種類
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Paris、フランス、75004
- Hôtel Dieu Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Common inclusion criteria:
- Age ≥ 18.
- Health care employees working in the EHPAD who consulted in the Hotel Dieu Hospital
- Affiliated with a health insurance
- Informed information and consent
Inclusion Criteria for Cases (asymptomatic COVID-19 patients) :
- Health care workers screened SARS-Cov-2 positive for NASopharyngeal swaths during screening campaigns for EHPAD staff.
- Having carried out a follow-up serology (M1 and M2) within the Hotel Dieu.
- Having never developed symptoms of COVID-19 or have developed some symptoms undetected before screening: fever, transient fatigue, rhinorrhea, symptoms that may be mistaken for a common winter cold (no respiratory symptoms or prolonged fever)
Inclusion criteria for controls (symptomatic COVID-19 patients) :
- Health care workers tested positive for polymerase chain reaction assay (PCR) SARS-Cov-2 during screening campaigns for EHPAD staff at the Hotel Dieu.
- Having carried out a follow-up serology (M1 and M2) within the Hotel Dieu.
COVID-19 symptoms defined by:
- At least two major signs of COVID-19 among: > fever, cough, chest tightness, bilateral pneumonia, anosmia, loss of taste.
- or a major sign and three minor signs among: headache, severe fatigue, diarrhea, odynophagia, rhinorrhea, suggestive skin signs.
It is part of the database of the virology department of Cochin Hospital (in case of failure to recruit health care workers in the EHPADs).
*Exclusion criteria :
- Refuse to participate or inability to obtain informed consent.
- under guardianship, curators
- negative SARS-COV-2 PCR
- Pregnancy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ふるい分け
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
他の:Cases
SARS-Cov-2 asymptomatic nursing homes employees
|
serology at M3 and serology at M6
|
他の:Controls
cohort of patients with a symptomatic COVID-19, preferably recruited in nursing homes or in case of difficulties in the virology service of COCHIN Hospital.
|
serology at M3 and serology at M6
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
rate of positive IgG serology
時間枠:month 1-2 post infection
|
positive IgG (Immunoglobulin G) SARS-Cov-2 serology after infection of asymptomatic employees
|
month 1-2 post infection
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
rate of positive IgG serology
時間枠:month 3-6 post infection
|
positive IgG (Immunoglobulin G) SARS-Cov-2 serology after infection of asymptomatic employees
|
month 3-6 post infection
|
rate of positive immunoglobulin M (IgM) serology
時間枠:month 1-2-3 and 6 post infection
|
positive IgM SARS-Cov-2 serology after infection of asymptomatic employees
|
month 1-2-3 and 6 post infection
|
rate of neutralizing antibodies
時間枠:month 1-2-3 and 6 post infection
|
concentration of neutralizing antibodies
|
month 1-2-3 and 6 post infection
|
questionnaire
時間枠:month 1-2-3 and 6 post infection
|
Associated factors with the presence of antibodies
|
month 1-2-3 and 6 post infection
|
re infection
時間枠:through study completion, an average of 8 months
|
of asymptomatic patients with SARS-Cov-2
|
through study completion, an average of 8 months
|
協力者と研究者
協力者
捜査官
- 主任研究者:Dominique Salmon, MD, PhD、Assistance Publique - Hôpitaux de Paris
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- APHP201253
- 2020-A01833-36 (その他の識別子:ID-RCB)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
COVID-19(新型コロナウイルス感染症)の臨床試験
-
Indonesia University募集COVID-19後症候群 | 長い COVID | COVID-19 後の状態 | COVID後症候群 | 長い COVID-19インドネシア
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, Indonesia募集COVID-19 パンデミック | COVID-19 ワクチン | COVID-19 ウイルス病インドネシア
-
Yang I. Pachankis積極的、募集していないCOVID-19 呼吸器感染症 | COVID-19 ストレス症候群 | COVID-19 ワクチンの副作用 | COVID-19 関連の血栓塞栓症 | COVID-19 集中治療後症候群 | COVID-19 関連の脳卒中中国
-
Massachusetts General Hospital募集
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin No.2 Hospital; Nuclear 215 Hospital of Shaanxi Province と他の協力者募集COVID-19(新型コロナウイルス感染症) | COVID-19後症候群 | ポスト急性COVID-19 | 急性 COVID-19中国
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention Srl完了COVID-19 の急性後遺症 | COVID-19 後の状態 | 長期COVID | 慢性新型コロナウイルス感染症(COVID-19)症候群イタリア
-
Endourage, LLC募集長い COVID | ロング Covid19 | ポスト急性COVID-19 | 長距離COVID | 長距離COVID-19 | ポスト急性COVID-19症候群アメリカ
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of Ioannina募集COVID-19 肺炎 | COVID-19 呼吸器感染症 | COVID-19 パンデミック | COVID-19 急性呼吸窮迫症候群 | COVID-19 関連肺炎 | COVID 19 関連の凝固障害 | COVID-19 (コロナウイルス病 2019) | COVID-19 関連の血栓塞栓症ギリシャ
-
Erasmus Medical CenterDa Vinci Clinic; HGC Rijswijkまだ募集していませんCOVID-19後症候群 | 長い COVID | ロング Covid19 | COVID-19 後の状態 | COVID後症候群 | COVID-19 後の状態、詳細不明 | 新型コロナウイルス感染症後の状況オランダ
-
Jonathann Kuo, MD積極的、募集していないSARS-CoV2感染 | COVID-19後症候群 | 自律神経失調症 | ポスト急性 COVID-19 症候群 | 長い COVID | ロング Covid19 | COVID-19 再発 | ポスト急性COVID-19 | COVID-19急性感染後 | COVID-19 の急性後遺症 | 自律神経失調症様障害 | 自律神経失調症 起立性低血圧症候群 | COVID-19 後の状態 | COVID後症候群 | COVID-19 後の状態、詳細不明アメリカ